FAQ on Quantum BioPharma Ltd.'s PET Tracer for Monitoring Myelin Integrity in Multiple Sclerosis

What is the significance of the PET tracer developed by Quantum BioPharma Ltd.?

The PET tracer, [18F]3F4AP, can detect differences in lesions in multiple sclerosis patients not visible on conventional MRI, serving as a potential biomarker for monitoring myelin integrity, demyelination, and treatment response.

How does Quantum BioPharma Ltd. plan to use this PET tracer?

Quantum BioPharma aims to apply this imaging technology to evaluate its investigational neuroprotective drug, Lucid-21-302 (Lucid-MS), designed to protect the myelin sheath in multiple sclerosis.

Who developed the PET tracer mentioned in the announcement?

The tracer, [18F]3F4AP, was developed by Dr. Pedro Brugarolas of Massachusetts General Hospital.

Where was the study on the PET tracer published?

The study was published in the European Journal of Nuclear Medicine and Molecular Imaging on August 5, 2025.

What is Lucid-MS?

Lucid-MS is Quantum BioPharma’s patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

What other areas does Quantum BioPharma Ltd. focus on besides multiple sclerosis?

Quantum BioPharma is dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.

How can investors stay updated on Quantum BioPharma Ltd.’s latest news?

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.

What is the relationship between Quantum BioPharma Ltd. and Unbuzzd Wellness Inc.?

Quantum BioPharma retains ownership of 20.10% of Unbuzzd Wellness Inc. as of June 30, 2025, and receives royalty payments from sales of unbuzzd(TM), with the agreement including specific terms on royalty percentages and total payments.